Spots Global Cancer Trial Database for Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions

Official Title: Radiologic Detection and Characterization of Benign and Malignant Liver Lesions in Contrast-Enhanced MRI

Study ID: NCT02156739

Conditions

Hepatocellular Carcinoma

Liver and Intrahepatic Bile Duct Disorder

Metastatic Malignant Neoplasm in the Liver

Primary Malignant Liver Neoplasm

Interventions

Contrast-enhanced Magnetic Resonance Imaging

Gadobutrol

Gadoxetate Disodium

Study Description

Brief Summary: This clinical trial studies contrast-enhanced magnetic resonance imaging (MRI) in detecting nonmalignant and malignant liver lesions. Diagnostic procedures, such as MRI, may help find and diagnose nonmalignant and malignant liver lesions. Contrast agents, such as gadoxetate disodium and gadobutrol, may help doctors to see MRI images more clearly.

Detailed Description: PRIMARY OBJECTIVES: I. To compare the specificity of contrast enhanced MRI using a liver specific agent Eovist (gadoxetate disodium) versus the combined use of Eovist and an intravascular-extracellular agent Gadavist (gadobutrol) for the radiologic detection and characterization of liver lesions via clinical stability and follow up imaging. OUTLINE: Patients receive gadoxetate disodium intravenously (IV) over 1 minute and undergo MRI. Patients then receive gadobutrol IV over 1 minute at the 20 minute mark during MRI.